Tag: fingolimod
Oumaima, Morocco
"Siempre tenemos la esperanza de que las cosas mejoren en el futuro y de que, algún día, consigamos encontrar una cura definitiva para la esclerosis múltiple. Hasta entonces, tenemos que seguir las investigaciones más recientes".
Our application to the Essential Medicines List
Efforts to improve access to MS treatments continue
Brain volume changes may be key indicator for MS progression
New research suggests the rate of brain atrophy, or brain shrinkage, may be an important indicator of disease progression in MS.
First therapy to treat pediatric MS approved in US
Fingolimod has been approved by the US Food and Drug Administration (FDA) as a treatment for children and young people aged 10 years and older with relapsing MS
A new fingolimod-like drug is safe in people with relapsing-remitting MS
A phase II trial shows safety and efficacy of amiselimod
Rebound syndrome after stopping fingolimod
Researchers find that suddenly stopping fingolimod may lead to severe worsening of symptoms in MS
Alternative to natalizumab in people at risk of a brain infection
Swedish study favours rituximab over fingolimod for those at risk of progressive multifocal leukoencephalopathy
Natalizumab is more effective than fingolimod in reducing relapses
French researchers compare oral and injectable drugs for relapsing-remitting MS
New drug ozanimod could be an effective alternative to fingolimod
An international study looks at the safety and efficacy of a drug similar to fingolimod
Fingolimod is not effective in primary progressive multiple sclerosis
A new trial has failed to show Fingolimod has any effect of in primary-progressive MS
Recommended treatment after stopping natalizumab
Switching from natalizumab to an alternative drug may prevent disease reactivation
Switching to second-line disease-modifying drugs
Study shows that switching to natalizumab is more effective than switching to fingolimod
Long-term efficacy, safety and tolerability of fingolimod
Fingolimod is effective in reducing relapses and brain volume loss
Disappointing results from fingolimod trial in primary progressive MS
The results suggest that primary progressive and relapsing forms of MS have different underlying mechanisms
Underweight women on fingolimod at higher risk of lymphopenia
Underweight women and patients with low baseline lymphocyte counts should be monitored more closely